chevron_leftBack
As of 13 June 2026, Outlook Therapeutics, Inc. has a market cap of $26.82M USD, ranking #35017 globally and #4844 in the United States.
It ranks #3158 in the Healthcare sector, and #1067 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$26.82MUSD
Enterprise Value
$54.37MUSD
Revenue (TTM)
$205.7KUSD
EBITDA (TTM)
-$58.82MUSD
Net Income (TTM)
-$102.86MUSD
PS Ratio
127.1
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Robert Jahr
open_in_new
Employees
17
Founded
2010
IPO
13 May 2016
Website
outlooktherapeutics.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -2.2% | -21% | 22% | -44% | -81% | -83% |
News
Loading...
OTLK Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
OTLK
Outlook Therapeutics Inc
ISIN: US69012T3059
Shares Out.:
Shares Outstanding:
148.587M1
Shares Float:
120.694M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
0.2564 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
3M%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
2M%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
1M%
|
97.4
|
|
NYSE: MRK
|
$274.03B
1M%
|
15.1
|
|
NYSE: PFE
|
$149.38B
557K%
|
19.5
|
|
NYSE: BMY
|
$117.58B
438K%
|
16.8
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SIX: RO
|
$321.52B
1M%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.84B
1M%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$274.65B
1M%
218.9B CHF
|
20.5
|
|
CPH: NOVO-B
|
$181.82B
678K%
1.18T DKK
|
11.5
|
|
EPA: SAN
|
$110.1B
410K%
95.26B EUR
|
19.9
|
|
LSE: GSK
|
$108.46B
404K%
80.96B GBP
|
14.6
|
chevron_leftBack